DICHLOROPHENYL-ABA
| 中文名称 | DICHLOROPHENYL-ABA |
|---|---|
| 中文同义词 | 化合物 T15116 |
| 英文名称 | DICHLOROPHENYL-ABA |
| 英文同义词 | benzoic acid, 2-[(3,5-dichlorophenyl)amino]-;Dichlorophenyl ABA,DichlorophenylABA |
| CAS号 | 18201-65-5 |
| 分子式 | C13H9Cl2NO2 |
| 分子量 | 282.12 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 18201-65-5.mol |
| 结构式 |  |
DICHLOROPHENYL-ABA 性质
| 熔点 | 245 °C |
|---|---|
| 沸点 | 420.8±45.0 °C(Predicted) |
| 密度 | 1.470±0.06 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | DMSO:~18 mg/mLat ~60 °C |
| 形态 | 固体 |
| 酸度系数(pKa) | 3.62±0.36(Predicted) |
| 颜色 | 白色 |
Transthyretin (TTR) amyloid fibril formation
Dichlorophenyl-ABA (DCPA) is able to prevent L55P aggregate formation in the conditioned medium. With regard to the ultrastructural analysis, Dichlorophenyl-ABA does not show an inhibitory effect as high as DFPB and benzoxazole, indicating that the Y78F mutant may not be as sensitive to this drug as TTR L55P and V30M are.
Dichlorophenyl-ABA is the best stabilizers of V30M tetramers in plasma from carriers of this mutant, and clearly inhibit aggregation in the cellular system. Therefore Dichlorophenyl-ABA is promising for the treatment of valine at position 30 (V30M)-associated familial amyloidotic polyneuropathy (FAP) but need to undergo further stages of drug development to overcome their toxicity.